Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MyVax misses Phase III endpoint

Genitope (GTOP) said MyVax personalized immunotherapy missed the primary endpoint of a significant improvement in progression-free survival (PFS)

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE